FLT3 and plasma cell myeloma: Future directions in CAR-NK research will involve novel targets such as fms-like tyrosine kinase 3 (FLT3) for leukemia as well as CD138 and CCND subset 1 (CS1) for multiple myeloma [94,95,96].